 |
SuzhouMay 12, 2026 /PRNewswire/ — Suzhou Ribolia Biopharmaceutical Co., Ltd. (Ribolia, 06938.HK) today announced the official signing of a strategic cooperation agreement with Insilico Medicine (03696.HK). The two parties will leverage their core strengths in small nucleic acid drug development and AI-driven pharmaceutical innovation to conduct in-depth collaboration in areas such as target discovery, drug molecule design and optimization, AI-assisted drug research and clinical translation. Together, they will advance demonstration projects and technology transfer, combining AI and siRNA innovation to accelerate the development of small nucleic acid drugs and address unmet clinical needs.
Small nucleic acid drugs utilize the RNAi mechanism to achieve precise silencing of disease-causing genes. With core advantages including broad target range, digital design capability, short development cycles, and high patient compliance due to ultra-long-lasting effects, they are leading the “third wave of modern pharmaceuticals.” The deep integration of artificial intelligence technology will further enhance the efficiency and success rate of siRNA drug development, accelerating breakthroughs in “undruggable” targets that are difficult to address with traditional methods, offering new treatment options for patients.
Ribolia is integrating AI technology into its small nucleic acid drug research and development system. It has established algorithm-driven platforms for intelligent siRNA sequence design and efficient ligand screening, enabling rapid identification, iteration, and optimization of high-quality candidate molecules. During the clinical development phase, AI technology is used to predict and evaluate the efficacy and safety of targets in patient populations, significantly improving the efficiency and success rate of clinical studies. Previously, Ribolia and Insilico Medicine had collaborated in the field of intelligent automated high-throughput screening. This strategic cooperation upgrade will leverage Ribolia’s deep industrial expertise and leading development capabilities in small nucleic acid technology and drug R&D, combined with Insilico Medicine’s AI technology empowerment system covering the entire new drug development process. This will achieve comprehensive complementary advantages and deep synergy, accelerating the development of innovative small nucleic acid drugs, addressing unmet clinical needs, and benefiting patients worldwide as soon as possible.
Dr. Ren Feng, Co-CEO and Chief Scientific Officer of Insilico Medicine, said: “We are very pleased to sign a strategic cooperation agreement with Ribolia today. Insilico Medicine and Ribolia have maintained close communication and mutual trust. Notably, in 2025, Ribolia became the first high-throughput experimental service partner of Insilico Medicine’s LifeStar 2 automated laboratory platform, demonstrating the platform’s value in empowering the industry. With continuous innovations in AI algorithms, Insilico Medicine’s Pharma.AI platform has recently undergone several major upgrades. After in-depth discussions, both parties have reached a consensus on collaboration opportunities to leverage the Pharma.AI platform in multiple scenarios for small nucleic acid drug development. We will jointly advance related collaborations, end-to-end empower the R&D of small nucleic acid therapies, further broaden the boundaries of AI empowerment, and strive to meet unmet clinical needs.”
Dr. Gan Liming, Co-CEO and Global R&D President of Ribolia, said: “We are already in a new era of AI-guided clinical R&D. Insilico Medicine and Ribolia are highly aligned in their innovation capabilities and mission visions in their respective fields. We are very pleased to reach a comprehensive strategic cooperation based on our previous smooth collaboration. Through years of technological accumulation and leveraging existing AI tools and methods, Ribolia has entered a rapid development phase with intensive output of candidate drugs and efficient advancement of clinical trials. We believe that with the support of Insilico Medicine’s globally leading AI application systems, this will provide a powerful booster for our differentiated strategic development stage. We look forward to sparking innovative ideas through close collaboration, further enhancing the efficiency and certainty of our drug R&D, and enabling AI-driven small nucleic acid therapies to benefit all of humanity as soon as possible.”
About Insilico Medicine
Insilico Medicine is a global pioneer biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery and drive innovation in life sciences, empowering humans to live longer and healthier lives. On December 30, 2025, Insilico Medicine was listed on the Main Board of the Hong Kong Stock Exchange under the stock code 03696.HK.
Utilizing its proprietary Pharma.AI platform and advanced automated biology laboratory, Insilico Medicine is providing innovative drug solutions for unmet disease areas such as fibrosis, oncology, immunology, pain, obesity, and metabolic disorders. Additionally, Insilico Medicine continues to expand the application of Pharma.AI into diverse fields, including advanced materials, agriculture, nutritional products, and veterinary medicine. For more information, please visit www.insilico.com.
About Ribolia:
Suzhou Ribolia Biopharmaceutical Co., Ltd. is a global biopharmaceutical company focused on the development and commercialization of small interfering RNA (siRNA) drugs. Powered by its independently innovative small nucleic acid technology platform, the company has built a rich and differentiated product pipeline targeting major disease areas such as cardiovascular metabolism, liver, and kidney diseases. Ribolia is committed to providing revolutionary treatment options for patients worldwide through continuous innovation. On January 9, 2026, Ribolia was listed on the Main Board of the Hong Kong Stock Exchange under the stock code 06938.HK. For more information, please visit www.ribolia.com.